Novo Nordisk Reports Doubling Wegovy Sales, Projects Slower Growth in 2025

The Danish pharmaceutical giant faces intensifying competition and supply challenges as it works to expand production and develop next-generation obesity treatments.

Novo Nordisk's Wegovy sales surged 107% in Q4 2024, contributing to a 26% annual revenue growth, but the company forecasts slower growth of 16% to 24% in 2025.
Eli Lilly remains a key competitor in the weight-loss drug market, with Novo Nordisk holding a 52% market share for GLP-1 medications like Wegovy and Ozempic.
Supply constraints continue to impact production, with the company investing in new manufacturing sites, including three acquired from Catalent in late 2024.
Novo Nordisk is focusing on next-generation drugs, such as CagriSema and amycretin, though early trial results for CagriSema fell short of investor expectations.
Medicare drug pricing negotiations and potential U.S. tariff risks add further pressure, while Novo Nordisk remains optimistic about long-term market expansion.

Investor's Business Daily